Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
NCT00834704 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2013-03-26
Summary
Open-label, multicenter, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study.
Conditions
Interventions
- DRUG
-
PEGPH20
PEGylated recombinant human hyaluronidase
Sponsors & Collaborators
-
Halozyme Therapeutics
lead INDUSTRY
Principal Investigators
-
Joy Zhu, M.D. · Halozyme Therapeutics
Study Design
- Allocation
- NON_RANDOMIZED
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-02-28
- Primary Completion
- 2012-06-30
- Completion
- 2012-11-30
Countries
- United States
Study Locations
More Related Trials
-
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors
NCT00909740 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
NCT02078752 ·Status: TERMINATED ·Phase: PHASE1
-
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
NCT04746612 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of HS-20122 in Patients With Advanced Solid Tumors
NCT06927570 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
NCT02222922 ·Status: COMPLETED ·Phase: PHASE1
-
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
NCT02805166 ·Status: COMPLETED ·Phase: PHASE4
-
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473 ·Status: RECRUITING ·Phase: PHASE1
-
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
NCT02030067 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
NCT03634982 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Intravenous RXDX-107 in Patients With Solid Tumors
NCT02548390 ·Status: TERMINATED ·Phase: PHASE1
-
Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
NCT00474760 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
NCT02298387 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
NCT00813384 ·Status: COMPLETED ·Phase: PHASE1
-
PTC596 in Patients With Advanced Solid Tumors
NCT02404480 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors
NCT00093873 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study of Oral DFP-11207 in Solid Tumors
NCT02171221 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
NCT01009190 ·Status: COMPLETED ·Phase: PHASE1
-
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
NCT05061537 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
NCT04628780 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
NCT06990698 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
NCT05194072 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of PYX-201 in Advanced Solid Tumors
NCT05720117 ·Status: RECRUITING ·Phase: PHASE1
-
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
NCT06365918 ·Status: WITHDRAWN ·Phase: PHASE1